NEWARK, Calif., September 6, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. CBAYa clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet needs, announced today that management will attend HC Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
| HC Wagner 24th Annual Global Investment Conference | ||
| Date: | Wednesday 14 September 2022 | |
| Time: | 11:30 a.m. Eastern Time / Fireside Chat | |
| web cast: | http://ir.cymabay.com/events | |
About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people living with liver disease and other chronic diseases who have significant unmet medical needs through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis and the unique targets involved in its progression has helped us achieve Breakthrough Therapy designation (US Food and Drug Administration), PRIORITY drug designation (European Medicines Agency) and to receive orphan drug designation (US and Europe) for Seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision making and commitment to the highest standards of quality reflect our relentless commitment to the people, families and communities we serve. To learn more, visit www.cymabay.com and keep following us Twitter and linkedin.
Warnings
Any statements made in this press release and at the conference referred to above regarding the potential of Seladelpar to treat PBC and potentially improve the clinical manifestations of the disease, the potential benefit to patients, the timing of the release of Seladelpar clinical data, future introduction and use currently approved therapies, expected evolution of the PBC treatment paradigm, future therapeutics, surrogate endpoints, potential target product profiles and potential quality of life…
